ROCHE HOLDINGS AG (RHHBY)

32.84
0.23 0.71
OTC
Prev Close 32.61
Open 32.74
Day Low/High 32.70 / 32.99
52 Wk Low/High 26.30 / 34.98
Volume 1.21M
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)
Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III IMpower132 study of TECENTRIQ ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial...

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be presented at the International Association for the Study of Lung...

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and...

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people...

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present 16 new data presentations across its Alzheimer's disease (AD) pipeline at this year's Alzheimer's Association International Conference (AAIC) from...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab)...

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms In People At High Risk Of Complications From The Flu

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms In People At High Risk Of Complications From The Flu

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study's primary...

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced submission of a supplemental New Drug Application (sNDA) to the U.

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced The Risk Of Disease Worsening Or Death In People With Metastatic Or Locally Advanced Triple Negative Breast Cancer

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced The Risk Of Disease Worsening Or Death In People With Metastatic Or Locally Advanced Triple Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression free survival (PFS).

FDA Grants Priority Review To Genentech's Baloxavir Marboxil For The Treatment Of Influenza

FDA Grants Priority Review To Genentech's Baloxavir Marboxil For The Treatment Of Influenza

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People With Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People With Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower133 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis.

Genentech Announces New OCREVUS (Ocrelizumab) Data On Long-Term Disability Benefits In Primary Progressive Multiple Sclerosis And Initiation Of Two Global Studies In Progressive MS

Genentech Announces New OCREVUS (Ocrelizumab) Data On Long-Term Disability Benefits In Primary Progressive Multiple Sclerosis And Initiation Of Two Global Studies In Progressive MS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 4 th Congress of the European Academy of Neurology (EAN) from June 16-19 in Lisbon, Portugal.

FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy As A Treatment For Women With Advanced Ovarian Cancer Following Initial Surgery

FDA Approves Genentech's Avastin (Bevacizumab) Plus Chemotherapy As A Treatment For Women With Advanced Ovarian Cancer Following Initial Surgery

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Announces FDA Approval For Venclexta Plus Rituxan For People With Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces FDA Approval For Venclexta Plus Rituxan For People With Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Priority Review To Genentech's HEMLIBRA (emicizumab-kxwh) For People With Hemophilia A Without Factor VIII Inhibitors

FDA Grants Priority Review To Genentech's HEMLIBRA (emicizumab-kxwh) For People With Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from the Phase III IMpower131 study showed TECENTRIQ ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE ® [albumin-bound paclitaxel;...

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today full results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in people with hemophilia A...

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced follow-up data from the Phase III ALEX study, showing that as an initial treatment Alecensa ® (alectinib) significantly reduced the risk of disease progression or death...

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Phase III results for HEMLIBRA ® (emicizumab-kxwh) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from May...

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMblaze370 study evaluating the combination of TECENTRIQ ® (atezolizumab) and COTELLIC ® (cobimetinib) did not meet its primary endpoint of overall...

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of...